NasdaqGS:IDYABiotechs
IDEAYA Biosciences (IDYA) Persistent Losses Challenge Bullish High Revenue Growth Narratives
IDEAYA Biosciences Q1 2026 Earnings: Revenue Context and Persistent Losses
IDEAYA Biosciences (IDYA) has just reported its Q1 2026 results, and investors are looking at them through the lens of a business that recently generated Q4 2025 revenue of US$10.9 million alongside a basic EPS loss of US$0.94 and a net loss of US$83.3 million. The company has seen quarterly revenue range from US$0 to US$207.8 million over the past year, with basic EPS swinging between a profit of US$1.35 and losses of...